Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × olaparib × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 8 Head and Neck Neoplasms 3 Carcinoma, Squamous Cell 3 Thyroid Neoplasms 1 Smoking 1 Ovarian Neoplasms 1 Nasopharyngeal Carcinoma 1 Laryngeal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Cisplatin 121 Gemcitabine 67 Radiotherapy, Intensity-Modulated 58 Docetaxel 36 toripalimab 34 Fluorouracil 34 Capecitabine 34 Radiotherapy 21 Drug Therapy 20 camrelizumab 19 nimotuzumab 18 spartalizumab 12 pembrolizumab 12 nedaplatin 12 apatinib 11 Induction Chemotherapy 11 sintilimab 10 Chemoradiotherapy 10 tislelizumab 9 Magnetic Resonance Spectroscopy 9 Carboplatin 9 Specimen Handling 8 Radiation 8 Nivolumab 8 Cetuximab 8 Bevacizumab 8 endostar protein 7 Paclitaxel 7 Immune Checkpoint Inhibitors 7 Endostatins 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04825990 2022-04-07

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡